Orum Therapeutics

• Oversee the external development of our Degrader-Antibody Conjugate (DAC) pipeline • Manage high-stakes projects at CROs, specifically overseeing the synthesis of proprietary molecular glue degrader payloads and their conjugation to therapeutic antibodies • Proactively identify and vet CROs that offer specialized expertise in relevant in-vitro activity assays, in vivo studies, linker-payload synthesis, and complex bioconjugation • Support the expansion of our TPD²® (Degradation) and TPS²™ (Stabilization) platforms by identifying specialized Chinese partners capable of advanced physics-based modeling and machine learning-driven payload design • Drive IND-enabling studies for candidates like ORM-1153 (CD123-targeting DAC) and support ongoing clinical-stage programs • Navigate the "China price" ecosystem to find cost-effective, high-quality alternatives for R&D without compromising the integrity of our AnDC™ (Antibody neoDegrader Conjugate) technology